Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Aug 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with extensive-stage small cell lung cancer (ES-SCLC) who have not yet received treatment. The trial will examine the combination of a medication called serplulimab, platinum-based chemotherapy, and aspirin to see if this combination can improve survival rates and overall health outcomes for patients. Small cell lung cancer is a serious condition that usually has a poor prognosis, and current treatments do not always provide the best results. By exploring this new combination, researchers hope to find a more effective option for patients.

To be eligible for this trial, participants must be at least 18 years old, have a confirmed diagnosis of ES-SCLC, and have not received any prior systemic treatments for their cancer. They should also have a measurable tumor and a good performance status, meaning they are generally able to carry out daily activities. If you join this trial, you will receive the combination treatment and be monitored closely for safety and effectiveness. The trial is not yet recruiting, but it aims to provide new insights into better treatment options for those facing this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males or females aged ≥ 18 years.
• • 2. Histologically or cytologically confirmed ES-SCLC (according to the Veterans Administration Lung Cancer Group \[VALG\] staging system).
• • 3. Treatment-naïve for systemic therapy targeting ES-SCLC.
• • 4. Patients must have at least one tumor lesion that meets the following criteria: previously untreated, accurately measurable, with a longest diameter ≥ 10 mm at baseline (for lymph nodes, short axis ≥ 15 mm), measurable by chest CT or PET-CT, as long as accurate repeat measurements can be performed.
• • 5. ECOG performance status score of 0 or 1.
• • 6. Expected survival ≥ 3 months.
• • 7. Planned treatment with Serplulimab combined with platinum-based chemotherapy.
• • 8. Patients who have previously taken or are currently taking Bayer Aspirin are allowed.
• Exclusion Criteria:
• • 1. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
• • 2. Currently receiving other anticoagulant therapy.
• • 3. Previous systemic anti-tumor therapy.
• • 4. Contraindications to the use of Serplulimab, Aspirin, or chemotherapy.